Navitor Pharmaceuticals to Present at UBS Global Healthcare Conference
Navitor Pharmaceuticals, Inc., is a biopharmaceutical company discovering and developing novel medicines that target the nutrient sensing pathways that regulate mTORC1, a master regulator of cellular growth and metabolism. The company’s proprietary drug discovery platform unlocks the therapeutic potential of mTOR by bringing together deep knowledge into nutrient sensors, proprietary biological tools and expertise regarding the correlation of mTORC1 activity in disease. Navitor’s small molecule therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activation to address a wide range of diseases, including neurological and fibrotic disorders, immunometabolism and certain rare diseases. The company’s founding intellectual property is based on groundbreaking discoveries related to the mTORC1 pathway and nutrient signaling mechanisms by Dr. David Sabatini at The Whitehead Institute for Biomedical Research. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, Johnson & Johnson Innovation – JJDC, Inc., SR One, Ltd., Brace Pharma Capital, Remeditex Ventures and Sanofi Ventures. For more information, please visit www.navitorpharma.com.
The Yates Network
Kathryn Morris, 914-204-6412
Source: Navitor Pharmaceuticals, Inc.